Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aptose Biosciences (APTO) today and set a price target of $12.00.

JonesTrading analyst Soumit Roy reiterated a Buy rating on Aptose Biosciences (APTO) today and set a price target of $14.00.

Oppenheimer analyst Rick Schafer maintained a Buy rating on Analog Devices (ADI) today. The company’s shares closed last Friday at $167.

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Mustang Bio (MBIO), with a price target of …

In a report released today, Chad Messer from Needham maintained a Buy rating on Autolus Therapeutics (AUTL), with a price target of $21.00.

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL), with a price target of …

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on X4 Pharmaceuticals (XFOR), with a price target of …

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG (CRSP) today. The company’s shares closed last Friday at $126.

In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI), with a price target of $26.00.

In a report issued on June 8, Andy Hsieh from William Blair reiterated a Buy rating on ImmunoGen (IMGN). The company’s shares closed …